Cancer diagnosis & prognosis最新文献

A Case of Infraorbital B-cell Lymphoma Masquerading as an Abscess.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10437

Saad Rashid, Mudassar Sandozi, Saagar Pamulapati, Ajay Doniparthi, Suneha Pocha, Mohammed Ahmed Khan

引用次数: 0

Predictive Factors for the Efficacy of Head and Neck Photoimmunotherapy and Optimization of Treatment Schedules.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10428

Daisuke Nishikawa, Takuya Shimabukuro, Hidenori Suzuki, Shintaro Beppu, Hoshino Terada, Yoshiaki Kobayashi, Nobuhiro Hanai

{"title":"Predictive Factors for the Efficacy of Head and Neck Photoimmunotherapy and Optimization of Treatment Schedules.","authors":"Daisuke Nishikawa, Takuya Shimabukuro, Hidenori Suzuki, Shintaro Beppu, Hoshino Terada, Yoshiaki Kobayashi, Nobuhiro Hanai","doi":"10.21873/cdp.10428","DOIUrl":"10.21873/cdp.10428","url":null,"abstract":"Background/aim: Head and neck photoimmunotherapy (HN-PIT) is a promising treatment for unresectable locally advanced or recurrent head and neck cancers. However, the optimal tumor characteristics and treatment schedules remain unclear. This study aimed to identify factors associated with treatment efficacy and assess the effectiveness of treatment schedules.Patients and methods: A retrospective cohort study of patients treated with HN-PIT at Aichi Cancer Center Hospital from January 2021 to October 2024 was conducted. Tumor characteristics, treatment cycles, and outcomes were analyzed. The thickness and longest diameter of the tumors were evaluated, and treatment intervals were assessed for their association with complete response (CR).Results: Among the 19 patients (30 cycles), CR was observed exclusively in local lesions. Smaller and thinner lesions showed significantly better treatment responses. Thinner lesions were more likely to achieve CR after a single cycle, whereas intermediate-thickness tumors often required multiple cycles with shorter intervals. The regional lesions did not achieve CR, even with multiple cycles and shorter intervals. Age was a significant factor influencing CR.Conclusion: HN-PIT demonstrated promising efficacy for local lesions, particularly for smaller and thinner lesions. Optimizing treatment schedules, including shorter intervals for intermediate lesions, is critical for improving outcomes. Further research is needed to enhance the efficacy for regional lesions and refine treatment schedules.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"179-188"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preoperative Visitation Effect on Quality of Life of Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10434

Toru Ishikawa, Atsuko Suzuki, Hiromi Yamamoto, Narumi Arita, Yusuke Matsuhashi, Nao Kobayashi, Eriko Nakagawa, Nanako Terai, Asami Hoshii, Terasu Honma

{"title":"Preoperative Visitation Effect on Quality of Life of Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma.","authors":"Toru Ishikawa, Atsuko Suzuki, Hiromi Yamamoto, Narumi Arita, Yusuke Matsuhashi, Nao Kobayashi, Eriko Nakagawa, Nanako Terai, Asami Hoshii, Terasu Honma","doi":"10.21873/cdp.10434","DOIUrl":"10.21873/cdp.10434","url":null,"abstract":"Background/aim: While transcatheter arterial chemoembolization (TACE) is a treatment option for patients with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma, it is associated with physical and psychological pain, with concerns regarding its effect on quality of life (QOL). In December 2020, we introduced radiology nurse-led preoperative visits to patients undergoing TACE. This study aimed to examine QOL improvement following a preoperative visit.Patients and methods: Among patients scheduled to undergo TACE for hepatocellular carcinoma, 48 received a preoperative visit and 22 did not (control group). We compared QOL variables between the groups using the Short-Form 36 (SF-36) at hospital admission and discharge.Results: No significant between-group differences in clinical backgrounds were observed. In the control group, SF-36 scores at admission/discharge were as follows: physical function (PF), 42.87±14.46/34.71±19.70 and mental health (MH), 51.32±8.67/45.26±11.35, respectively. In the subgroup analysis, the PF/MH item results were PF 40.89±14.55/31.46±19.25 and MH 51.10±9.07/44.79±12.04 for older adult patients in the control group. In the preoperative visit group, PF (admission, 42.31±14.23; discharge, 41.54±14.12; p=0.989) and MH (admission, 48.45±10.97; discharge, 49.59±10.05; p=0.399) were maintained.Conclusion: PF/MH items at admission and discharge were maintained or improved in the preoperative visit group, whereas those in the control group showed a significant decrease. Preoperative visits contributed to maintaining patient QOL.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"230-237"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of HMGA1 and Height in Breast Cancer Risk and Prognosis: Insights from UK Biobank Data.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10424

Steven Lehrer, Peter H Rheinstein

{"title":"The Role of HMGA1 and Height in Breast Cancer Risk and Prognosis: Insights from UK Biobank Data.","authors":"Steven Lehrer, Peter H Rheinstein","doi":"10.21873/cdp.10424","DOIUrl":"10.21873/cdp.10424","url":null,"abstract":"Background/aim: Tall women are more likely to develop breast cancer (BC). High Mobility Group AT-Hook 1 (HMGA1), an oncofetal protein, plays a role in BC progression. Variants near HMGA1 have been associated with increased height. This study examines the relationship between HMGA1, height, and BC risk and prognosis using UK Biobank data.Patients and methods: Data from 10,527 women with invasive BC were analyzed. Subjects were grouped by height: short (<155 cm), medium (155-175 cm), and tall (>175 cm). HMGA1 SNP rs41269028, a single nucleotide intron variant, was evaluated for its influence on height, BC risk, and survival. Statistical analysis included Fisher's exact test, regression models, and survival analysis using the log-rank test.Results: HMGA1 SNP rs41269028 carriers (CT+TT) were taller (162.88 cm) compared to homozygotes for the major allele (162.29 cm, p=0.005). Tall women with BC showed poorer survival than short women (p=0.032). However, HMGA1 genotype did not significantly affect BC risk (p=0.602) or survival (p=0.439). Multivariate analysis confirmed an independent effect of age and HMGA1 genotype on height.Conclusion: While HMGA1 influences height, no direct association with increased BC risk or poor prognosis in tall women was demonstrated. Nevertheless, tall women with BC had worse survival, suggesting height might be considered in treatment decisions. Future studies should explore mechanisms linking height to BC outcomes.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"146-152"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinicopathological Features and Prognosis of Unresectable Colorectal Cancer With the BRAF V600E Mutation.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10432

Yukari Ono, Koji Numata, Kenta Iguchi, Mamoru Uchiyama, Masahiro Asari, Yasushi Rino, Aya Saito, Manabu Shiozawa

{"title":"Clinicopathological Features and Prognosis of Unresectable Colorectal Cancer With the BRAF V600E Mutation.","authors":"Yukari Ono, Koji Numata, Kenta Iguchi, Mamoru Uchiyama, Masahiro Asari, Yasushi Rino, Aya Saito, Manabu Shiozawa","doi":"10.21873/cdp.10432","DOIUrl":"10.21873/cdp.10432","url":null,"abstract":"Background/aim: Patients with unresectable advanced and recurrent colorectal cancer (CRC) and the BRAF V600E mutation have poor prognosis, and conventional chemotherapy is often ineffective. This study aimed to retrospectively evaluate the clinicopathological features and prognosis of this patient population.Patients and methods: We examined clinicopathological characteristics and treatment outcomes of 26 patients with BRAF V600E-mutated unresectable advanced and recurrent CRC treated between June 2015 and October 2022.Results: The mean age was 63.1±14.0 years; out of 26 patients, nine (34.6%) were female, 12 (46.2%) had right-sided CRC, and eight (30.8%) had poorly differentiated or mucinous adenocarcinoma. One patient (3.8%) had a RAS mutation, and three (11.5%) had high microsatellite instability. The median overall survival (OS) was 12.0 months. The median OS for patients treated with the BEACON regimen (encorafenib plus cetuximab, with or without binimetinib) was 13.3 months, which was significantly better than that of patients treated without it (7.2 months; hazard ratio=4.180, 95% confidence interval=1.036-18.631, p=0.029). The median progression-free survival for patients treated with BEACON regimen was 6.6 months.Conclusion: The BRAF V600E mutation was associated with poor prognosis. The BEACON regimen resulted in improved OS compared with other CRC treatment regimens.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"216-222"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of PI3K Levels and miRNA124-5p Expression Levels in Serum Samples from Patients With Lung Cancer.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10433

Fatma Tuba Akdeniz, Orcun Avsar

{"title":"Evaluation of PI3K Levels and miRNA124-5p Expression Levels in Serum Samples from Patients With Lung Cancer.","authors":"Fatma Tuba Akdeniz, Orcun Avsar","doi":"10.21873/cdp.10433","DOIUrl":"10.21873/cdp.10433","url":null,"abstract":"Background/aim: Lung cancers are malignant neoplasms located in the lung tissues. miRNAs are short non-coding RNAs. It is known that miRNA-124 prevents metastasis in lung cancers. The phosphatidylinositol 3-kinases (PI3K) signaling pathway, a basic signaling pathway interconnected with other pathways, is activated during cancer development. This study aimed to compare miRNA-124-5p and PI3K serum levels in patient and control groups.Materials and methods: miRNA isolated from patient and control serum samples were converted into cDNA. miRNA-124-5p expression was determined using Real-Time PCR and a SYBR GREEN kit. PI3K serum level was determined using the Enzyme-Linked Immunosorbent Assay.Results: While miRNA-124-5p serum level was statistically significantly lower in the patient group (p>0.02), serum PI3K level was higher in the patient group than in the control group but the difference was not statistically significant (p>0.11).Conclusion: Lower serum levels of miRNA-124-5p and high PI3K levels observed in the patient group, compared to the control group, may be associated with a poor disease prognosis.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"223-229"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term Outcomes of Salvage Radiotherapy Using TomoTherapy With Image-guided Radiotherapy for Postoperative Prostate Cancer Patients.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10429

Yuki Mukai, Motoko Omura, Yumiko Minagawa, Misato Mase, Yuta Nishikawa, Ichiro Miura, Masaharu Hata

{"title":"Long-term Outcomes of Salvage Radiotherapy Using TomoTherapy With Image-guided Radiotherapy for Postoperative Prostate Cancer Patients.","authors":"Yuki Mukai, Motoko Omura, Yumiko Minagawa, Misato Mase, Yuta Nishikawa, Ichiro Miura, Masaharu Hata","doi":"10.21873/cdp.10429","DOIUrl":"10.21873/cdp.10429","url":null,"abstract":"Background/aim: This study aimed to evaluate the long-term outcomes, treatment-related toxicity, and factors affecting postoperative prostate cancer patients treated with intensity-modulated radiation therapy and image-guided radiation therapy (IMRT-IGRT) using TomoTherapy as salvage radiotherapy (SRT).Patients and methods: A total of 71 consecutive patients who underwent SRT after radical prostatectomy between 2011 and 2023 were included in the study. Treatment outcomes, including the progression-free rate (PFR) and overall survival, were calculated using Kaplan-Meier curves. Associations between treatment outcomes and factors were analyzed using the Cox proportional hazards regression analysis.Results: The median follow-up time after SRT was 60 months (range=1-148 months). The 5-year and 10-year PFR were 69.05% and 54.73%, respectively. In multivariate analysis, maximum PSA >0.7 ng/ml was significantly associated with worse PFR (p<0.05). Additionally, eight patients (11.3%) experienced late grade 2 genitourinary toxicity, and one (1.4%) patient developed late grade 2 gastrointestinal toxicity. No adverse events were rated higher than grade 3.Conclusion: Our findings demonstrate a comparable PFR at 5-year (69.05%) and 10-year (54.73%) intervals with those of previous reports, confirming the efficacy of IMRT-IGRT as a viable option for SRT. Worse PFR was associated with factors such as mass PSA >0.7 ng/ml, providing critical insights into prognostication. SRT for prostate cancer with IMRT and IGRT using TomoTherapy showed similar treatment outcomes and low toxicity rates compared with those of previous studies.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"189-197"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Malignant Peripheral Nerve Sheath Tumor (MPNST) Arising from Orbital Plexiform Neurofibroma in a Small Child With Neurofibromatosis Type 1.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10436

Reinhard E Friedrich, Christian Hagel

{"title":"Malignant Peripheral Nerve Sheath Tumor (MPNST) Arising from Orbital Plexiform Neurofibroma in a Small Child With Neurofibromatosis Type 1.","authors":"Reinhard E Friedrich, Christian Hagel","doi":"10.21873/cdp.10436","DOIUrl":"10.21873/cdp.10436","url":null,"abstract":"Background/aim: Neurofibromatosis type 1 (NF1) is an autosomal dominant hereditary tumor predisposition syndrome. In approximately 30% of cases, plexiform neurofibromas (PNFs) are identified, which are precursor lesions for malignant peripheral nerve sheath tumors (MPNSTs). MPNST is a major cause of the reduced life expectancy of NF1 patients.Case report: The patient, a two-year-old at the time of surgical treatment, had been diagnosed with an orbital nerve sheath tumor causing lid swelling and ptosis since birth. The tumor showed disproportionately rapid growth, leading to increasing functional (mechanical) restrictions in lid elevation. Surgical exploration of the orbit indicated a PNF with areas of a MPNST. Two months later, a new biopsy confirmed the MPNST. The tumor was treated with multimodal chemotherapy. After completion of chemotherapy, orbital exenteration was performed. The tissue specimens only comprised tissue of a benign PNF. However, within six months, the patient developed an intracranial recurrence and died from a rapidly growing intracerebral tumor fraction, which histologically proved to be a MPNST.Conclusion: Orbital PNF is a rare and characteristic manifestation of facial NF1. Typically, tumors in this localization are associated with severe functional disabilities and aesthetic disfigurement, resulting from invasive tumor growth and skeletal deformities. Histological classification of the tumors may be challenging due to varying histological differentiation in different tumor locations. Thus, early diagnosis with representative tumor sampling and complete histological work-up of the specimen together with multimodal therapy are essential prerequisites to overcome the poor prognosis of these tumors.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"244-254"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Third Liver Resection for Re-recurrent Hepatocellular Carcinoma: Assessment of the Prognostic Factors of Long-term Survival.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10426

Mayuko Kori, Kei Shimada, Takuya Hashimoto

{"title":"Third Liver Resection for Re-recurrent Hepatocellular Carcinoma: Assessment of the Prognostic Factors of Long-term Survival.","authors":"Mayuko Kori, Kei Shimada, Takuya Hashimoto","doi":"10.21873/cdp.10426","DOIUrl":"10.21873/cdp.10426","url":null,"abstract":"Background/aim: Second hepatic resection is a well-established and effective treatment for recurrent hepatocellular carcinoma (HCC). Despite this, the recurrence rate of HCC remains high. The efficacy of third liver resection for re-recurrent HCC is uncertain, and prognostic factors affecting survival after third hepatectomy have not been comprehensively evaluated. This study aimed to investigate the short- and long-term outcomes of third liver resection for re-recurrent HCC and identify prognostic factors affecting survival.Patients and methods: In total, 27 patients who underwent three liver resections for primary, recurrent, and re-recurrent HCC were retrospectively reviewed. The prognostic factors of long-term survival were evaluated using clinical data including those of previous liver resections.Results: No cases of perioperative mortality after third liver resection for re-recurrent HCC were found. The median overall survival and disease-free survival were 38.3 and 5.8 months, respectively. The 5-year overall survival and disease-free survival rates were 56.8% and 10.9%, respectively. Clinical parameters such as tumor marker level, primary tumor size, and surgical interval of the third liver resection and of the first and second surgeries were significantly associated with long-term survival.Conclusion: The survival rate of third liver resection for re-recurrent HCC in our study was similar to that reported for second and third hepatectomies in previous studies. Clinical information on previous surgeries could be a useful determinant of third liver resection for re-recurrent HCC.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"162-170"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Body Mass Index on Survival After Docetaxel Chemotherapy for Metastatic Castration-resistant Prostate Cancer.

Cancer diagnosis & prognosis Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.21873/cdp.10423

Carsten Nieder, Luka Stanisavljevic, Astrid Dalhaug, Ellinor Christin Haukland

{"title":"Impact of Body Mass Index on Survival After Docetaxel Chemotherapy for Metastatic Castration-resistant Prostate Cancer.","authors":"Carsten Nieder, Luka Stanisavljevic, Astrid Dalhaug, Ellinor Christin Haukland","doi":"10.21873/cdp.10423","DOIUrl":"10.21873/cdp.10423","url":null,"abstract":"Background/aim: Several recent studies, varying in design and the number of baseline parameters analyzed, suggest that a lower body mass index (BMI) is associated with shorter survival in men beginning treatment for metastatic castration-resistant prostate cancer (MCRPC), including treatments such as docetaxel. This study aimed to analyze the impact of BMI and numerous covariates on survival in a homogeneously treated cohort of Caucasian men who received first-line docetaxel for MCRPC.Patients and methods: This retrospective analysis included 112 consecutive patients managed between 2009 and 2023. Comorbidity, medications, and blood tests were included. Both, uni- and multivariate tests were performed.Results: The median age of the patients was 70 years with a median BMI of 26.8 kg/m2. Most patients were free from serious comorbidities, had bone-only metastases, and experienced metachronous development of metastases. Hemoglobin values were significantly lower in patients with lower BMI (median 11.9 versus 13.0 g/dl, p=0.001). Lean patients had numerically shorter survival compared to overweight/obese patients (median 11.8 versus 19.4 months, p=0.15). In multivariate analysis of prognostic factors, only three baseline parameters retained statistical significance: serum lactate dehydrogenase (p=0.03), hemoglobin (p=0.007), and the presence of non-bone metastases (p=0.004).Conclusion: An interaction between BMI and hemoglobin was present in metastatic castration-resistant prostate cancer patients after docetaxel chemotherapy, explaining the observed survival difference between lean and overweight/obese patients. Comorbidities and medications had no significant impact on survival in this population with limited prognosis (median survival 16.1 months).","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"138-145"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0